Los Angeles Capital Management’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $577K | Sell |
69,489
-1,429
| -2% | -$14.8K | ﹤0.01% | 825 |
|
|
2025
Q4 | $911K | Sell |
70,918
-63,982
| -47% | -$686K | ﹤0.01% | 660 |
|
|
2025
Q3 | $1.19M | Buy |
+134,900
| New | +$1.05M | ﹤0.01% | 658 |
|
|
2024
Q3 | – | Sell |
-178,840
| Closed | -$1.22M | – | 1202 |
|
|
2024
Q2 | $1.22M | Sell |
178,840
-15,151
| -8% | -$65.2K | ﹤0.01% | 589 |
|
|
2024
Q1 | $491K | Buy |
193,991
+32,460
| +20% | +$73.2K | ﹤0.01% | 875 |
|
|
2023
Q4 | $388K | Sell |
161,531
-11,184
| -6% | -$26.3K | ﹤0.01% | 945 |
|
|
2023
Q3 | $587K | Buy |
172,715
+82,996
| +93% | +$460K | ﹤0.01% | 781 |
|
|
2023
Q2 | $659K | Buy |
89,719
+45,255
| +102% | +$420K | ﹤0.01% | 765 |
|
|
2023
Q1 | $461K | Buy |
+44,464
| New | +$537K | ﹤0.01% | 876 |
|
|
2022
Q1 | – | Sell |
-8,733
| Closed | -$380K | – | 1428 |
|
|
2021
Q4 | $380K | Sell |
8,733
-8,892
| -50% | -$402K | ﹤0.01% | 1136 |
|
|
2021
Q3 | $882K | Buy |
17,625
+8,460
| +92% | +$512K | ﹤0.01% | 805 |
|
|
2021
Q2 | $577K | Buy |
9,165
+250
| +3% | +$16.1K | ﹤0.01% | 1114 |
|
|
2021
Q1 | $828K | Sell |
8,915
-5,705
| -39% | -$584K | ﹤0.01% | 983 |
|
|
2020
Q4 | $1.31M | Sell |
14,620
-219
| -1% | -$20.1K | 0.01% | 815 |
|
|
2020
Q3 | $1.53M | Buy |
14,839
+440
| +3% | +$47.4K | 0.01% | 657 |
|
|
2020
Q2 | $1.14M | Sell |
14,399
-1,785
| -11% | -$133K | 0.01% | 796 |
|
|
2020
Q1 | $936K | Hold |
16,184
| – | – | 0.01% | 728 |
|
|
2019
Q4 | $873K | Sell |
16,184
-6,745
| -29% | -$366K | ﹤0.01% | 878 |
|
|
2019
Q3 | $1.2M | Sell |
22,929
-200
| -0.9% | -$9.32K | 0.01% | 763 |
|
|
2019
Q2 | $1.12M | Hold |
23,129
| – | – | 0.01% | 813 |
|
|
2019
Q1 | $1.17M | Sell |
23,129
-290
| -1% | -$17.1K | 0.01% | 802 |
|
|
2018
Q4 | $1.39M | Sell |
23,419
-4,220
| -15% | -$272K | 0.01% | 645 |
|
|
2018
Q3 | $1.82M | Sell |
27,639
-1,772
| -6% | -$103K | 0.01% | 691 |
|
|
2018
Q2 | $1.49M | Sell |
29,411
-4,270
| -13% | -$222K | 0.01% | 783 |
|
|
2018
Q1 | $1.77M | Sell |
33,681
-30,255
| -47% | -$1.51M | 0.01% | 669 |
|
|
2017
Q4 | $2.97M | Buy |
63,936
+37,874
| +145% | +$1.59M | 0.02% | 556 |
|
|
2017
Q3 | $1.05M | Buy |
26,062
+18,360
| +238% | +$664K | 0.01% | 804 |
|
|
2017
Q2 | $261K | Sell |
7,702
-2,810
| -27% | -$86.7K | ﹤0.01% | 1096 |
|
|
2017
Q1 | $305K | Buy |
+10,512
| New | +$320K | ﹤0.01% | 1011 |
|
|
2016
Q4 | – | Sell |
-6,573
| Closed | -$207K | – | 1179 |
|
|
2016
Q3 | $207K | Buy |
+6,573
| New | +$191K | ﹤0.01% | 1160 |
|
|
2016
Q2 | – | Sell |
-19,854
| Closed | -$722K | – | 1246 |
|
|
2016
Q1 | $722K | Sell |
19,854
-22,036
| -53% | -$778K | 0.01% | 715 |
|
|
2015
Q4 | $1.68M | Sell |
41,890
-1,420
| -3% | -$49.5K | 0.02% | 545 |
|
|
2015
Q3 | $1.23M | Buy |
43,310
+22,240
| +106% | +$733K | 0.01% | 641 |
|
|
2015
Q2 | $694K | Buy |
+21,070
| New | +$653K | 0.01% | 851 |
|
|
2013
Q4 | – | Sell |
-18,565
| Closed | -$354K | – | 1284 |
|
|
2013
Q3 | $354K | Buy |
18,565
+370
| +2% | +$6.61K | ﹤0.01% | 1031 |
|
|
2013
Q2 | $262K | Buy |
+18,195
| New | +$263K | ﹤0.01% | 1121 |
|
Other funds holding EBS
VCM
PCM
VPM
Los Angeles Capital Management's EBS Position: Q1 2026 in Review
Los Angeles Capital Management reduced its Emergent Biosolutions (EBS) stake by 2% in Q1 2026, selling an estimated $14.8K and leaving 69,489 shares worth $577K. The position accounts for ﹤0.01% of the portfolio, ranked #825.
Los Angeles Capital Management first reported a position in EBS in Q2 2013 and has held it in 36 quarters since. The position peaked at $2.97M in Q4 2017. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.
- Los Angeles Capital Management held 69,489 shares of Emergent Biosolutions worth $577K as of Q1 2026.
- Los Angeles Capital Management sold 1,429 Emergent Biosolutions shares in Q1 2026, an estimated $14.8K.
- Emergent Biosolutions made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #825 holding.
- Los Angeles Capital Management first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 36 quarters since.
- Los Angeles Capital Management's Emergent Biosolutions position peaked at $2.97M in Q4 2017.
- 190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.
Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.